Loading...
XMAD
ATRY
Market cap226mUSD
Oct 20, Last price  
2.66EUR
1D
0.38%
1Q
6.40%
Jan 2017
79.73%
IPO
58.33%
Name

Atrys Health SA

Chart & performance

D1W1MN
XMAD:ATRY chart
P/E
—
P/S
1.43
EPS
—
Vol. 1Y
29.79%
Shs. 5Y
21.81%
Rev. 5Y
33.06%
Div Yld LY
—
Div Yld TTM
—
Revenues
141m
-33.72%
1,079,2731,018,9041,089,6162,865,8865,962,6228,029,4227,294,14314,836,66733,808,000121,014,000158,366,000201,569,000212,743,000141,007,000
Net income
-100m
L+215.65%
681,811336,533320,1981,294,79163,042290,94011,985-104,785-5,548,000-23,197,000-23,147,000-45,590,000-31,774,000-100,296,000
CFO
-2m
L
000409,89501,316,73101,083,498-1,395,9324,694,000-15,434,000-1,093,0002,997,000-1,559,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Atrys Health, S.A., a biomedical enterprise founded in 2007 and based in Madrid, Spain, specializes in providing a range of diagnostic services and medical treatments. Its diagnostic portfolio encompasses areas like pathology, hematology, molecular pathology, and genetics, supplemented by offerings such as diagnostic second opinions, a comprehensive test directory, and support for clinical trials and research & development. The company effectively utilizes telemedicine to deliver its expertise in medical specialties including radiology, cardiology, ophthalmology, and dermatology. Furthermore, Atrys Health administers radiotherapy and is engaged in the development of innovative therapeutic approaches and diagnostic instruments. The organization operated as Althia Health, S.L. before rebranding to Atrys Health, S.A. in May 2016.

Related entities

Subsidiaries (4)
ATRYS HEALTH INTERNACIONAL SA
EDIAGNOSTIC CLINICA VIRTUAL DE ESPECIALIDADES MEDICAS S.L.(SOCIEDAD UNIPERSONAL)
ASPY PREVENCION S.L. (SOCIEDAD UNIPERSONAL)

Key people

Santiago De Torres Sanahuja
Chairman of the Board, Other External Director · since 2025
Jose Maria Huch Ginesta
Chief Financial Officer · since 2015
Luis De Gregorio Cudos
Director - Finance · since 2021
Juan Mella
Country Manager, Chile, Director - Business Development, Latin America · since 2024
Pedro Salord Betrand
Chief Human Resource Officer · since 2021
Luis Duran Vizan
Global Chief Technology Officer · since 2023
Encarna Vega
Chief Administrative Officer · since 2007
Alfonso Alba
Partner, Vice President - Genetics · since 2020
Benjamin Guix
Vice President - Oncology, Medical Director of IMOR · since 2019
Garbriela Camunas Caruana
General Counsel · since 2020
Ana Alarcon Perez
Managing Director - Prevention
Maria Antonia Isach Gabaldon
Managing Director - Oncology · since 2022
Nicolas Achkar Tuglaman
Director - Clinical Telemedicine · since 2018
Graca Andrade Pires
Country Manager, Portugal · since 2021
Diana Barriga Rodriguez
Director - Communication and Culture
Ana Belen Galvan
Director - Technical · since 2011
Severino Gonzalez
Chief Technology Officer - Genetics
Victor Gonzalez-Rumayor
Director - Research and Development · since 2015
Gabriela Guzman Martinez
Medical Director - Cardiology · since 2015
Ignacio Hernandez
Director - Big Data
IPO date
Jul 22, 2016
Employees
1,928
Domiciled in
ES
Incorporated in
ES
Headquarters & legal address
Calle Velázquez 157 4 A
Madrid 28002
ES

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT